MindWalk Unveils Biological Context Layer for AI Drug Discovery at AMD Event
At AMD's Advancing AI 2026 event in San Francisco, MindWalk Holdings Corp. (NASDAQ: HYFT) demonstrated ReefIQ™, a biological context layer designed to enhance AI drug discovery by connecting fragmented data into a unified framework. The platform aims to address the limitations of current models that lack integrated biological understanding. MindWalk's approach involves three layers—HYFT for representation, ReefIQ for governance and organization, and LensAI for reasoning—to create a comprehensive system where AI can operate over interconnected biological information. This demonstration marks the first public showcase of ReefIQ in action on AMD Instinct hardware. The event highlights growing investor interest in AI-driven drug discovery, with companies like Recursion Pharmaceuticals (NASDAQ: RXRX), Absci (NASDAQ: ABSI), Tempus AI (NASDAQ: TEM), and NVIDIA (NASDAQ: NVDA) also active in the space. MindWalk's CEO emphasized that durable competitive advantage lies not just in models but in the biological context they can reason over.
Tickers: $ABSI $AMD $NVDA $RXRX $TEM
Topics: artificial intelligence biotech innovation drug discovery